Day-9 Anemia After an Uneventful Transfusion
A 62-year-old woman with myelodysplastic syndrome and a history of two prior pregnancies but no transfusions is admitted with fatigue. Hemoglobin is 6.8 g/dL and platelets are 38 × 10^9/L; the hematologist orders 2 units of RBCs. The pretransfusion type is O positive with a negative antibody screen (gel, anti-IgG/C3d). She receives both units uneventfully and is discharged. On day 9 she returns with dyspnea. Hemoglobin is 6.9 g/dL, though it had risen to 9.4 g/dL after transfusion. Total bilirubin is 3.1 mg/dL, LDH 720 U/L, haptoglobin <10 mg/dL, and reticulocytes are 5.8%. The new antibody screen is positive (2+ at AHG), the autocontrol is negative, and the reference laboratory identifies anti-Jka. The DAT is positive with anti-IgG 2+ and anti-C3d negative.
1. Interpret these findings. What is the diagnosis, and what evidence excludes a febrile non-hemolytic or allergic reaction?
Read the worked answer
The picture is a delayed hemolytic transfusion reaction (DHTR).
Supporting evidence
- The hemoglobin fell to below the pretransfusion value at day 9 after an appropriate initial increment, meaning donor cells were destroyed after a period of survival.
- Biochemical hemolysis: indirect hyperbilirubinemia, high LDH, undetectable haptoglobin, reticulocytosis.
- Serologic proof: positive DAT with IgG only (coating of circulating donor cells), negative autocontrol (not autoimmune), and a newly identified alloantibody, anti-Jka, directed at a low-frequency-of-detection but common Kidd antigen.
Why not the alternatives
- A febrile non-hemolytic reaction occurs during or within hours of transfusion, does not produce a positive DAT, and does not cause a 2.5 g/dL fall a week later.
- An allergic reaction produces urticaria or anaphylaxis without hemolysis, without a positive DAT, and without a delayed drop.
- A negative autocontrol makes autoimmune hemolysis unlikely; a negative autocontrol with a positive screen and positive DAT in a recently transfused patient points to an alloantibody.
Note that the DAT can be only weakly positive or even negative in some DHTRs because the antibody titer is low and donor cells are cleared quickly; a negative DAT would not exclude the diagnosis when the other findings fit.
2. What must be done before any further RBC transfusion, and what must be reported and to whom?
Read the worked answer
Before the next transfusion
- Transfuse Jka-negative units. Crossmatch by AHG/gel rather than electronically, since the patient now has a clinically significant antibody.
- Phenotype (or genotype) the patient's red cells for Kidd plus Rh, Kell, Duffy, and MNS to guide antigen selection and to predict which additional antibodies she is at risk of making. Chronically transfused patients such as this one benefit from prophylactic phenotype matching.
- Check the historical record every time: the anti-Jka is a permanent serologic fact even when the screen later becomes negative.
- Issue a medical alert card and enter a permanent comment in the LIS/blood bank record.
Reporting
- Complete a transfusion reaction report and submit it to the hospital transfusion committee / hemovigilance system; DHTRs are reportable events in most hemovigilance schemes.
- Notify the ordering clinician with the interpretation and the requirement for antigen-negative units.
- Notify the blood supplier only if donor lookback is relevant - generally not required for a delayed reaction, but document the decision.
Clinical follow-up Monitor urine output, creatinine, and hemoglobin; renal injury is uncommon but possible. Recheck the antibody screen 4–8 weeks later, since additional antibodies may become detectable.
3. Why was anti-Jka missed on the pretransfusion sample, and which laboratory practice most reduces the chance of this recurring?
Read the worked answer
Why it was missed Antibody screening has a detection threshold (method dependent, roughly 0.3–0.5 IU/mL of antibody). After a first immunizing exposure, the titer decays over months to years and frequently falls below that threshold. The pretransfusion sample was drawn while the antibody was undetectable - not because the method was wrong, but because there was nothing to detect. Re-exposure to Jka-positive donor cells triggered an anamnestic response, so by day 9 the titer was high enough both to coat transfused cells (positive DAT) and to react in the screen.
The single most effective practice Treat the patient's antibody history as a permanent, hard-stop record: query prior records before every type and screen and every crossmatch. If a patient has a documented clinically significant antibody, select antigen-negative units regardless of a currently negative screen. Supplemental measures:
- Prophylactic phenotype matching for patients likely to be chronically transfused (MDS, sickle cell disease, thalassemia).
- Recheck the screen and DAT whenever a post-transfusion hemoglobin falls unexpectedly.
- Use a method with adequate sensitivity and include IgG-sensitized and unensitized cells in the panel; document method changes.
This case is a process lesson as much as a serologic one: the antibody was 'known' only in retrospect, and a record check is what converts retrospect into foresight.